RT Journal Article
SR Electronic
T1 Donanemab outperformed Aducanumab and Lecanemab on cognitive, but not on biomarker and safety outcomes: systematic review, frequentist and Bayesian network meta-analyses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.31.24305134
DO 10.1101/2024.03.31.24305134
A1 Jeremic, Danko
A1 Navarro-López, Juan D.
A1 Jiménez-Díaz, Lydia
YR 2024
UL http://medrxiv.org/content/early/2024/04/01/2024.03.31.24305134.abstract
AB INTRODUCTION Questions remain regarding safety and clinical relevance of anti-amyloid antibodies in Alzheimer’s disease (AD), with no scientific basis for choosing between different therapies.METHODS Systematic review, frequentist and Bayesian network meta-analyses of phase III randomized placebo-controlled trials were performed to comparatively evaluate cognitive, functional and biomarker efficacy and safety of anti-amyloid antibodies in sporadic AD. Treatments were ranked with P- and SUCRA scores, with rank robustness measured by Cohen’s kappa, and uncertainty in ranking probabilities estimated with Shannon’s normalized entropy.RESULTS Based on data from 16,971 patients (16 studies), we found Donanemab the best-ranked antibody on cognitive measures. Lecanemab was the most effective at reducing amyloid burden. Caution is needed concerning brain edema and microbleeding, with clinically important risks for Donanemab, Aducanumab and Lecanemab.DISCUSSION Risk/benefit profile of anti-amyloid antibodies remains unfavorable. Patients in Donanemab study were stratified by tau load, with greater effects observed in low/medium tau population.HighlightsNo single therapy ranked the best among all outcomes.Donanemab was the most effective antibody at reducing cognitive decline across all primary outcomes, while Lecanemab ranked the highest on amyloid PET removal.Consistently greater cognitive, functional and biomarker effects of Donanemab were observed in patients with low/medium tau load, suggesting more promising effects in earlier AD stages.All antibodies, except Solanezumab, were significantly less tolerable than Placebo.The risk of cerebral edema and microbleeding may outweigh the benefits, independently of APOE status.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants PID2020-115823-GB100 funded by MCIN/AEI/10.13039/501100011033, and SBPLY/21/180501/000150 funded by JCCM/ERDF A way of making Europe, and 2022-GRIN-34354 grant by UCLM/ERDF intramural funding to LJ-D and JDN-L.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors